IL1B and Sepsis: Furthermore, a causative role for IL-1β has been shown in clinical trials using recombinant IL-1 receptor antagonists to inhibit IL-1 signaling, effectively reducing mortality from 65 to 35% in patients with sepsis and HBD + DIC [13].